David Borges Sells 30,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Omeros Trading Up 3.6%

Shares of OMER traded up $0.46 during midday trading on Wednesday, hitting $13.08. 1,873,513 shares of the company’s stock traded hands, compared to its average volume of 3,674,355. Omeros Corporation has a 1 year low of $2.95 and a 1 year high of $17.65. The firm’s fifty day moving average is $10.81 and its 200-day moving average is $6.82. The stock has a market capitalization of $927.37 million, a price-to-earnings ratio of -6.48 and a beta of 2.38.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. On average, equities research analysts anticipate that Omeros Corporation will post -3.09 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Saturday. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Thursday, January 8th. HC Wainwright raised their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $40.33.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently made changes to their positions in OMER. Vanguard Group Inc. increased its position in shares of Omeros by 1.9% during the third quarter. Vanguard Group Inc. now owns 3,346,958 shares of the biopharmaceutical company’s stock worth $13,723,000 after purchasing an additional 63,381 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after buying an additional 263,095 shares in the last quarter. Marshall Wace LLP raised its position in shares of Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after buying an additional 97,224 shares during the last quarter. Bank of Montreal Can lifted its stake in shares of Omeros by 1.4% in the second quarter. Bank of Montreal Can now owns 571,095 shares of the biopharmaceutical company’s stock worth $1,713,000 after buying an additional 8,000 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Omeros by 1,201.1% in the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after buying an additional 384,168 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.